LATAM AF Ablation Registry
NCT07924202, Not yet recruiting, Latin American Heart Rhythm Society
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | LATAM AF Ablation Registry | ClinicalTrials.gov |
| NCT number | NCT07924202 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 1,600 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Latin American Heart Rhythm Society | ClinicalTrials.gov |
| Conditions | Atrial Fibrillation (AF) | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Occurrence of any procedure-related complication (acute or late) | During 12 months follow-up | The primary safety outcome is the occurrence of any procedure-related complication, including acute (defined as those ocurring during the procedure or the first week after the procedure) and late (defined as those occurring after on week after the procedure). These include: * Number of patients presenting pericardial effusion, cardiac tamponade, thromboembolism, vascular access site lesion, pulmonary vein stenosis, esophageal ulcer, atrioesophageal fistula * Percentage of patients presenting all-cause death. | ClinicalTrials.gov |
| Primary | The primary effectiveness outcome | 8 weeks after ablation, up until the expected 12 month follow-up | The primary effectiveness outcome is arrhythmia recurrence, defined as the number of patients with documentation of an atrial arrhythmia lasting more than 30 seconds during follow-up after an 8-week blanking period. | ClinicalTrials.gov |
| Secondary | Reduction in AF burden | During 12 month follow'up | In patients with an cardiac implantable electronic device (CIED), AF burden will be measured before the procedure and during follow-up | ClinicalTrials.gov |
| Secondary | Change in atrial fibrillation-related symptoms | During 12-month follow-up | Change in AF-related symptoms, as determined by EHRA symptom classification. | ClinicalTrials.gov |
| Other | Procedural characteristics | During the procedure | Procedural characteristics, including procedural time, fluoroscopy time, lesion set, type of enegy used, concomitant left atrial appendage occlusion | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)